ETR:EVT

Evotec - EVT Stock Forecast, Price & News

€18.17

-0.98 (-5.12%)

(As of 10/5/2022 12:00 AM ET)

Add

Compare

Today's Range: €18.00
▼
€19.40
50-Day Range: €17.34
▼
€29.09
52-Week Range: €17.19
▼
€45.47

Volume: 372,571 shs
Average Volume: 1.36 million shs
Market Capitalization: $3.22 billion

P/E Ratio: 454.25
Dividend Yield: N/A
Price Target: €37.83

About Evotec (ETR:EVT) Stock

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Receive EVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

EVT Stock News Headlines

September 21, 2022 | markets.businessinsider.com

Adapsyn Bioscience enters into strategic collaboration with Evotec

September 20, 2022 | markets.businessinsider.com

EQS-News: Just Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program

September 20, 2022 | finance.yahoo.com

Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program

September 16, 2022 | markets.businessinsider.com

DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)

August 25, 2022 | finanznachrichten.de

Evotec SE: Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany

August 25, 2022 | markets.businessinsider.com

DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany

August 4, 2022 | finance.yahoo.com

Evotec SE Reports First Half-year 2022 Results on 11 August 2022

July 6, 2022 | markets.businessinsider.com

DGAP-News: Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

July 6, 2022 | finance.yahoo.com

Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance

July 5, 2022 | markets.businessinsider.com

DGAP-News: Evotec completes acquisition of Rigenerand

June 22, 2022 | markets.businessinsider.com

DGAP-News: Evotec SE reports results of Annual General Meeting 2022

June 14, 2022 | markets.businessinsider.com

DGAP-News: Evotec enters a drug discovery collaboration with Janssen

May 31, 2022 | finanznachrichten.de

Evotec AE: Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand

May 30, 2022 | markets.businessinsider.com

DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand

May 11, 2022 | uk.finance.yahoo.com

Evotec SE reports results for the first quarter 2022 and provides corporate update

May 11, 2022 | markets.businessinsider.com

DGAP-News: Evotec SE reports results for the first quarter 2022 and provides corporate update

May 10, 2022 | markets.businessinsider.com

DGAP-Adhoc: Evotec and Bristol Myers Squibb extend and expand strategic partnership

April 12, 2022 | finance.yahoo.com

Secarna Pharmaceuticals' Strategic Partner Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb

April 12, 2022 | markets.businessinsider.com

DGAP-News: Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures

April 8, 2022 | finanznachrichten.de

Evotec AG: Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb

March 21, 2022 | markets.businessinsider.com

DGAP-News: Evotec receives 3 m milestone payment for Bayer starting Phase II clinical development of DNP programme

March 2, 2022 | markets.businessinsider.com

DGAP-News: Evotec presents strategic roadmap towards precision medicine and confirms goals of Action Plan 2025 at Capital Markets Day

March 2, 2022 | apnews.com

Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets Day

March 1, 2022 | markets.businessinsider.com

DGAP-News: Evotec expands molecular patient database with unique nephrotic syndrome cohort from the University of Bristol

February 15, 2022 | finance.yahoo.com

IMIDomics, Inc. Announces Strategic Investment from Drug Discovery and Research Leader Evotec SE

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive EVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

EVT Company Calendar

Today: 10/05/2022
Next Earnings (Estimated): 11/09/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: ETR
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: ETR:EVT
CUSIP: N/A
CIK: N/A
Web: www.evotec.com
Phone: +49-40-560810
Fax: N/A
Employees: 4,081
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: €37.83
High Stock Price Forecast: €47.00
Low Stock Price Forecast: €30.00
Forecasted Upside/Downside: +108.2%
Consensus Rating: N/A
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 454.25
Forward P/E Ratio: 107.00
P/E Growth: 2.08
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 37.88
Current Ratio: 3.57
Quick Ratio: 3.24

Sales & Book Value

Annual Sales: $683.61 million
Price / Sales: 4.70
Cash Flow: €5.23 per share
Price / Cash Flow: 3.47
Book Value: €7.22 per share
Price / Book: 2.52

Miscellaneous

Outstanding Shares: 176,952,992
Free Float: N/A
Market Cap: $3.22 billion
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. Werner Lanthaler M.B.A. (Age 54)
MBA, MPA, Ph.D., Chairman of Management Board & CEO
Comp: $1.3M

Mr. Enno Spillner (Age 52)
CFO & Member of Management Board
Comp: $604k

Dr. Cord Dohrmann Ph.D. (Age 58)
Chief Scientific Officer & Member of Management Board
Comp: $726k

Dr. Craig Johnstone (Age 52)
COO & Member of Management Board
Comp: $616k

Dr. Matthias Evers (Age 49)
Chief Bus. Officer & Member of Management Board

Ms. Anja Bosler
Principal Accounting Officer and Sr. VP of Group Accounting

Mr. Volker Braun
Sr. VP and Global Head of Investor Relations & ESG

Dr. Christian Dargel
EVP Global Head of Legal & Compliance

Gabriele Hansen
Sr. VP & Head of Global Corp. Communications & Marketing

Ms. Monika Conradt
Global Head of HR

Key Competitors

View All Competitors

EVT Stock - Frequently Asked Questions

What is Evotec's stock price forecast for 2022?: 0 analysts have issued 12-month price targets for Evotec's shares. Their EVT share price forecasts range from €30.00 to €47.00. On average, they predict the company's share price to reach €37.83 in the next year. This suggests a possible upside of 97.6% from the stock's current price.
View analysts price targets for EVT or view top-rated stocks among Wall Street analysts.
How have EVT shares performed in 2022?: Evotec's stock was trading at €42.50 on January 1st, 2022. Since then, EVT shares have decreased by 54.9% and is now trading at €19.15.
View the best growth stocks for 2022 here.
When is Evotec's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our EVT earnings forecast.
What other stocks do shareholders of Evotec own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven Pharmaceutical (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC).

What is Evotec's stock symbol?: Evotec trades on the ETR under the ticker symbol "EVT."
What is Evotec's stock price today?: One share of EVT stock can currently be purchased for approximately €19.15.
How much money does Evotec make?: Evotec (ETR:EVT) has a market capitalization of $3.39 billion and generates $683.61 million in revenue each year.
How many employees does Evotec have?: The company employs 4,081 workers across the globe.
How can I contact Evotec?: Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The official website for the company is www.evotec.com. The company can be reached via phone at +49-40-560810.

This page (ETR:EVT) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms